AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Syndax Pharmaceuticals, Inc.
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001T92272
13.40▼ 0.17 (-1.25%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
13.57
Day's Range
13.20 – 13.61
52-Week Range
12.80 – 25.59
Volume
4.2M
Avg Volume
2.3M
Share Statistics
Shares Outstanding
Employees
298
Exchange
XNAS
Listed
2016-03-03
Share count as of July 31, 2026

Syndax Pharmaceuticals, Inc. (SNDX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Syndax Pharmaceuticals, Inc. (SNDX)
What is Syndax Pharmaceuticals, Inc.'s Market Cap?
Syndax Pharmaceuticals, Inc.'s Market Cap is $1.2B, based on as-reported figures from SEC (XBRL) filings.
What is Syndax Pharmaceuticals, Inc.'s Enterprise Value?
Syndax Pharmaceuticals, Inc.'s Enterprise Value is $992.7M, based on as-reported figures from SEC (XBRL) filings.
What is Syndax Pharmaceuticals, Inc.'s Price / Sales?
Syndax Pharmaceuticals, Inc.'s Price / Sales is 4.7×, based on as-reported figures from SEC (XBRL) filings.
What is Syndax Pharmaceuticals, Inc.'s EV / Revenue?
Syndax Pharmaceuticals, Inc.'s EV / Revenue is 3.9×, based on as-reported figures from SEC (XBRL) filings.
What is Syndax Pharmaceuticals, Inc.'s EV / EBITDA?
Syndax Pharmaceuticals, Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Syndax Pharmaceuticals, Inc.'s Revenue (TTM)?
Syndax Pharmaceuticals, Inc.'s Revenue (TTM) is $252.3M, based on as-reported figures from SEC (XBRL) filings.
What is Syndax Pharmaceuticals, Inc.'s Net Income (TTM)?
Syndax Pharmaceuticals, Inc.'s Net Income (TTM) is -$220.8M, based on as-reported figures from SEC (XBRL) filings.
What is Syndax Pharmaceuticals, Inc.'s EBITDA?
Syndax Pharmaceuticals, Inc.'s EBITDA is -$179.2M, based on as-reported figures from SEC (XBRL) filings.
What is Syndax Pharmaceuticals, Inc.'s Diluted EPS (TTM)?
Syndax Pharmaceuticals, Inc.'s Diluted EPS (TTM) is -2.47, based on as-reported figures from SEC (XBRL) filings.
What is Syndax Pharmaceuticals, Inc.'s EBITDA Margin?
Syndax Pharmaceuticals, Inc.'s EBITDA Margin is -71.0%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · SNDXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Total revenues
YoY growth+91.8%+223.6%+794.9%+267.0%
Operating expenses:
Cost of Product Sales
Research and development
Selling, general and administrative
Collaboration loss———
Total operating expenses
% of revenue154.9%152.7%191.0%225.2%
Loss from operations
% of revenue-54.9%-52.7%-91.0%-125.2%
Other income (expense), net:
Royalty interest expense
Convertible note interest expense———
Other interest expense
Interest income
Other expense
Total other (expense) income, net
Net loss
% of revenue-67.8%-65.8%-99.0%-132.4%
Basic loss per share attributable to common stockholders
Diluted loss per share attributable to common stockholders